62491-Apetoh, Lionel

Lionel Apetoh, MSC, PhD

Director, Brown Center for Immunotherapy Immune Monitoring Core

975 W. Walnut St.
IB 554B

Indianapolis, IN 46202

Key Publications

  • Benoit-Lizon I, Jacquin E, Rivera Vargas T, Richard C, Roussey A, Dal Zuffo L, Martin T, Mélis A, Vinokurova D, Shahoei SH, Baeza Garcia A, Pignol C, Gioguitti S, Carapito R, Boidot R, Végran F, Flavell RA, Ryffel B, Nelson ER, Soulas-Spaurel P, Lawrence T, Apetoh L 

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of Th1 and Th9 cells. J Immunother Cancer, 2022 Jan;10(1):e003459.

  • Dosset M, Rivera Vargas T, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L 

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology, 2018 Mar 15;7(6):e1433981.

  • Rivera Vargas T, Cai Z, Shen Y, Dosset M, Benoit-Lizon I, Martin T, Roussey A, Flavell RA, Ghiringhelli F, Apetoh L

Selective   degradation    of   the   PU.1   transcription    factor   during   autophagy   represses differentiation and antitumor activity of Th9 cells. Nat. Commun., 2017 Sep 15;8(1):559.

  • Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rébé C, Dérangère V, Ryffel B, Kato M, Prévost-Blondel A, Ghiringhelli F, Apetoh L 

IRF1 dictates the IL-21-dependent anticancer functions of Th9 cells. Nat. Immunol., 2014 Aug;15(8):758-66.

  • Berger H, Végran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangère V, Chevriaux A, Rébé C, Pot C, Ryffel B, Hichami A, Desvergnes B, Ghiringhelli F, Apetoh L

SOCS3 transactivation by PPARg prevents IL-17-driven cancer growth. Cancer Res. , 2013 Jun 15;73(12):3578-90.

  • Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L*, Ghiringhelli F*

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the NLRP3 inflammasome and promotes tumor growth. Nat. Med., 2013 Jan;19(1):57-64.* Contributed equally

  • Sakuishi K*, Apetoh L*, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC 

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010 Sep 27;207(10):2187-94. *Contributed equally 

  • Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK 

The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 2010 Sep;11(9):854-61.

  • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G and Zitvogel L

Toll-like Receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007 Sep:13(9):1050-1059.

Titles & Appointments

  • Director, Brown Center for Immunotherapy Immune Monitoring Core
  • Christopher Brown Professor of Immunology
  • Professor of Microbiology & Immunology
  • Education
    2008 PhD University of Paris
    2004 MSC University of Strasbourg
  • Research
    I am an immunologist with a strong expertise in adaptive immune responses to cancer. Challenging the view that chemotherapies only mediate their anticancer activity through a direct cytotoxic activity on tumor cells, my Ph.D. work uncovered a critical contribution of anticancer immune responses for the success of conventional therapies. This work prompted the design of novel strategies enhancing the efficacy of anticancer therapies by manipulating the immune system. During my postdoctoral work at Harvard University, I underscored the relevance of concomitant Tim-3 and PD-1 blockade to prevent T cell dysfunction and restore anticancer immunity. After returning to France, I set up my laboratory and showed the anticancer properties of a novel subset of CD4 T cells, IL-9-producing TH9 cells, upon adoptive transfer against melanoma. Thanks to funding from the European Commission, I developed in my laboratory multiple models of combination treatments with chemotherapy and immunomodulation to interrogate the relevance of T cells in anticancer cancer immune responses. In January 2023, I joined the Brown Center for Immunotherapy (Indianapolis, IN) as Christopher Brown Professor of Immunology to pursue the discovery of novel molecular targets that can be therapeutically exploited to enhance T cell functions. For this, my laboratory will combine in vitro and in vivo approaches including advanced gene and protein expression analysis of mouse and human T cells, immunological investigation of the anticancer responses in transgenic, gene-deficient mice as well as spontaneous and transplantable models of cancers.

Research Labs

Faculty research at IU School of Medicine is transforming health. Details about the medical research being conducted in faculty labs throughout IU School of Medicine are available in the Research section of this site.

Faculty Labs